1740 related articles for article (PubMed ID: 18419392)
1. The safety profile of varicella vaccine: a 10-year review.
Galea SA; Sweet A; Beninger P; Steinberg SP; Larussa PS; Gershon AA; Sharrar RG
J Infect Dis; 2008 Mar; 197 Suppl 2():S165-9. PubMed ID: 18419392
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP).
Goulleret N; Mauvisseau E; Essevaz-Roulet M; Quinlivan M; Breuer J
Vaccine; 2010 Aug; 28(36):5878-82. PubMed ID: 20600487
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain.
Sauerbrei A; Eichhorn U; Gawellek S; Egerer R; Schacke M; Wutzler P
J Med Virol; 2003 Oct; 71(2):313-9. PubMed ID: 12938208
[TBL] [Abstract][Full Text] [Related]
4. The postmarketing safety profile of varicella vaccine.
Sharrar RG; LaRussa P; Galea SA; Steinberg SP; Sweet AR; Keatley RM; Wells ME; Stephenson WP; Gershon AA
Vaccine; 2000 Nov; 19(7-8):916-23. PubMed ID: 11115716
[TBL] [Abstract][Full Text] [Related]
5. Different genotype pattern of varicella-zoster virus obtained from patients with varicella and zoster in Germany.
Sauerbrei A; Wutzler P
J Med Virol; 2007 Jul; 79(7):1025-31. PubMed ID: 17516537
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-strain varicella zoster virus causing recurrent herpes zoster in an immunocompetent 2-year-old.
Ota K; Kim V; Lavi S; Ford-Jones EL; Tipples G; Scolnik D; Tellier R
Pediatr Infect Dis J; 2008 Sep; 27(9):847-8. PubMed ID: 18664930
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of clinical varicella-zoster strains from India and differentiation from the oka vaccine strain.
Kaushik KS; Lahiri KK; Chumber SK; Gupta RM; Kumar S; Kapila K; Karade S
Jpn J Infect Dis; 2008 Jan; 61(1):65-7. PubMed ID: 18219137
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of single nucleotide polymorphisms used to differentiate vaccine and wild type strains of varicella-zoster virus.
Quinlivan M; Gershon AA; Steinberg SP; Breuer J
J Med Virol; 2005 Jan; 75(1):174-80. PubMed ID: 15543576
[TBL] [Abstract][Full Text] [Related]
9. Ten year follow-up of healthy children who received one or two injections of varicella vaccine.
Kuter B; Matthews H; Shinefield H; Black S; Dennehy P; Watson B; Reisinger K; Kim LL; Lupinacci L; Hartzel J; Chan I;
Pediatr Infect Dis J; 2004 Feb; 23(2):132-7. PubMed ID: 14872179
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.
Silber JL; Chan IS; Wang WW; Matthews H; Kuter BJ
Pediatr Infect Dis J; 2007 Jul; 26(7):572-6. PubMed ID: 17596796
[TBL] [Abstract][Full Text] [Related]
11. Rapid molecular discrimination between infection with wild-type varicella-zoster virus and varicella vaccine virus.
Lässker U; Harder TC; Hufnagel M; Suttorp M
Infection; 2002 Oct; 30(5):320-2. PubMed ID: 12382096
[TBL] [Abstract][Full Text] [Related]
12. Development of varicella vaccine.
Takahashi M; Asano Y; Kamiya H; Baba K; Ozaki T; Otsuka T; Yamanishi K
J Infect Dis; 2008 Mar; 197 Suppl 2():S41-4. PubMed ID: 18419406
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic understanding and control of varicella-zoster virus infection.
Asano Y
Vaccine; 2008 Nov; 26(50):6487-90. PubMed ID: 18694794
[TBL] [Abstract][Full Text] [Related]
14. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005.
Chaves SS; Haber P; Walton K; Wise RP; Izurieta HS; Schmid DS; Seward JF
J Infect Dis; 2008 Mar; 197 Suppl 2():S170-7. PubMed ID: 18419393
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.
Leung TF; Li CK; Hung EC; Chan PK; Mo CW; Wong RP; Chik KW
Eur J Haematol; 2004 May; 72(5):353-7. PubMed ID: 15059071
[TBL] [Abstract][Full Text] [Related]
16. [Immunization against varicella and zoster].
Floret D
Bull Acad Natl Med; 2007 Jun; 191(6):1051-64; discussion 1064-7. PubMed ID: 18402164
[TBL] [Abstract][Full Text] [Related]
17. [Modelling the impact of vaccination on the epidemiology of varicella zoster virus].
Bonmarin I; Santa-Olalla P; Lévy-Bruhl D
Rev Epidemiol Sante Publique; 2008 Oct; 56(5):323-31. PubMed ID: 18951741
[TBL] [Abstract][Full Text] [Related]
18. Chickenpox vaccines: new drugs. A favourable risk-benefit balance in some situations.
Prescrire Int; 2005 Jun; 14(77):85-91. PubMed ID: 15977369
[TBL] [Abstract][Full Text] [Related]
19. The effect of vaccination on the epidemiology of varicella zoster virus.
Edmunds WJ; Brisson M
J Infect; 2002 May; 44(4):211-9. PubMed ID: 12099726
[TBL] [Abstract][Full Text] [Related]
20. DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine.
Loparev VN; Rubtcova E; Seward JF; Levin MJ; Schmid DS
J Infect Dis; 2007 Feb; 195(4):502-10. PubMed ID: 17230409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
